Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes: An Effectiveness-Implementation Hybrid Type 1 Randomized Trial

NCT07797036 is registered in ClinicalTrials.gov with University of Massachusetts, Worcester as lead sponsor.

NCT NCT07797036
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07797036 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes: An Effectiveness-Implementation Hybrid Type 1 Randomized Trial
Lead sponsor
University of Massachusetts, Worcester
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
September 1, 2027
Completion date
December 31, 2030
Enrollment
226 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gestational diabetes mellitus (gdm), metabolic syndrome